Oncopeptides

Oncopeptides, a Stockholm-based company founded in 2000, specializes in creating medications for the treatment of cancer. The creators of Oncopeptides include some of Sweden's top oncology, clinical, and medical researchers, many of whom have achieved international recognition in their professions.


Melflufen, the first peptidase-potentiated cytotoxic medication designed for use in the treatment of multiple myeloma, was created by Oncopeptides. Oncopeptides has collaborated with eminent scientists and organizations in Europe and the US, such as the Dana Farber Cancer Institute of Harvard Medical School. Data from two phase I/II studies of its medication, melflufen, were presented by researchers in June 2019 at the European Haematology Association in Amsterdam. In 2017, Oncopeptides were listed on the Nasdaq Stockholm.


For difficult-to-treat hemophilia illnesses, Oncopeptides is creating novel therapeutic candidates. The development is based on their Peptide Drug Conjugate (PDC) and Small Polypeptide-based Killer Engagers (SPiKE) technologies and enables us to grow into new indications and build a strong pipeline.



Founded: 2000

Number of employees: 76 employees

Headquarters: Stockholm, Sweden

Website: https://www.oncopeptides.com/en

Photo by Drew Hays on Unsplash
Photo by Drew Hays on Unsplash
Penser Play

Top 8 Largest Biotech Companies In Sweden

  1. top 1 Hansa Biopharma
  2. top 2 Camurus AB
  3. top 3 Genovis AB
  4. top 4 BioArctic
  5. top 5 Oncopeptides
  6. top 6 Orexo
  7. top 7 Immunicum
  8. top 8 BioInvent

Toplist Joint Stock Company
Address: 3rd floor, Viet Tower Building, No. 01 Thai Ha Street, Trung Liet Ward, Dong Da District, Hanoi City, Vietnam
Phone: +84369132468 - Tax code: 0108747679
Social network license number 370/GP-BTTTT issued by the Ministry of Information and Communications on September 9, 2019
Privacy Policy